Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | oxidoreductase-like protein | 0.0361 | 0 | 0.5 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0361 | 0 | 0.5 |
Onchocerca volvulus | 0.0455 | 0.0189 | 1 | |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0361 | 0 | 0.5 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0361 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.5335 | 1 | 1 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0361 | 0 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.5335 | 1 | 1 |
Leishmania major | pteridine reductase 1 | 0.0361 | 0 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0361 | 0 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0361 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0361 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0361 | 0 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.5335 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0455 | 0.0189 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.5335 | 1 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.5335 | 1 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.5335 | 1 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0361 | 0 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.5335 | 1 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.5335 | 1 | 1 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0361 | 0 | 0.5 |
Trypanosoma brucei | pteridine reductase 1 | 0.0361 | 0 | 0.5 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0361 | 0 | 0.5 |
Echinococcus multilocularis | tumor protein p63 | 0.3111 | 0.553 | 1 |
Echinococcus granulosus | tumor protein p63 | 0.3111 | 0.553 | 1 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0455 | 0.0189 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.49 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.481 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.371 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.359 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.266 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.257 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.